Liquidia Corp
Liquidia Corp is a U.S.-based biopharmaceutical company focused on rare cardiopulmonary diseases, especially pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It develops and commercializes inhaled therapies built around its proprietary PRINT particle-engineering platform, with current revenue coming from YUTREPIA and a U.S. profit-sharing promotion agreement with Sandoz.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaApproved and marketed therapies sold directly to patients and providers, led by YUTREPIA.
Profit-sharing revenue from commercial activities tied to Sandoz Treprostinil Injection in the U.S.
Development of L606 and other PRINT-enabled product opportunities that are not yet commercial.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products93,7 %
- Services6,3 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Liquidia sells into the U.S. cardiopulmonary specialty care ecosystem, where physicians treat patients with PAH and PH-ILD and pharmacies/distributors handle access and reimbursement. Its commercial model depends on prescribers, hospital pharmacies, and payors that influence adoption of inhaled treprostinil therapies, while Sandoz-related revenue comes from the U.S. generic treprostinil market.
Pulmonary hypertension specialists who prescribe YUTREPIA or support Treprostinil Injection use because of efficacy, convenience, and dosing profile.
Clinicians treating PH-ILD patients who may adopt YUTREPIA for an inhaled treprostinil option in a difficult disease area.
Pharmacies that distribute the product and manage fulfillment, reimbursement, and patient access.
Commercial and government payors that determine formulary access, rebates, and patient affordability.
Sandoz buys promotion support and shares profits from Treprostinil Injection sales in the U.S.
Strategia
Liquidia’s near-term strategy is to scale YUTREPIA after its May 2025 FDA approval and June 2025 launch, while using a targeted field force to build prescriber and reimbursement adoption. Longer term, the company is trying to extend its PRINT platform and advance L606 and other pipeline opportunities to broaden its respiratory and vascular disease franchise.
Approved product sales are now the main direct revenue engine and must offset development spending.
Adoption depends on payor coverage, gross-to-net performance, and specialty pharmacy execution.
L606 and PRINT-based programs are needed to diversify the company beyond a single commercial product.
Maantiede
Liquidia is overwhelmingly U.S.-centric: YUTREPIA commercialization began in the United States, and the Sandoz promotion agreement also relates to U.S. Treprostinil Injection sales. The company’s operations are concentrated in Morrisville, North Carolina, with laboratory, manufacturing, and office leases supporting development and commercialization activities.
Riskit
Liquidia faces high execution risk because it depends on a newly launched product, a narrow disease focus, and third-party manufacturing and supply chains. It also faces litigation, reimbursement pressure, and financing risk typical of development-stage biopharma companies, while its U.S. operating concentration makes disruptions in one geography especially important.
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company has significant development and commercialization needs and may need additional capital on unfavorable terms.
Kohdistuu: Ongoing operations and pipeline funding
- Single-source manufacturing and supply dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on third parties for active ingredient, device, encapsulation, and packaging, so any disruption can delay supply and commercialization.
Kohdistuu: YUTREPIA and L606
- Patent and Hatch-Waxman litigationVaikutus: KorkeaTodennäköisyys: Kohtalainen
505(b)(2) products can face patent disputes that delay approval, restrict labeling, or force costly settlements.
Kohdistuu: Treprostinil-based products
- Commercial launch and reimbursement riskVaikutus: Korkea
YUTREPIA is newly launched, so uptake depends on physician adoption, payor coverage, and gross-to-net performance.
Kohdistuu: U.S. PAH and PH-ILD market
- Operational concentration in North CarolinaVaikutus: KeskitasoTodennäköisyys: Kohtalainen
A localized disruption could affect lab, manufacturing, and office operations and is not easily diversified.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätYUTREPIA sales are recorded net of rebates, chargebacks, discounts, returns, and other incentives, which can materially reduce reported revenue.
Vaikutus: Affects product sales timing and net revenue margin
Service revenue from the Sandoz agreement depends on underlying sales volumes and managed care adjustments.
Vaikutus: Can cause volatility in service revenue and margins
Non-cancelable product manufacturing and supply commitments create future cash outflows that must be disclosed and monitored.
Vaikutus: Affects liquidity and operating flexibility
Laboratory, manufacturing, and office leases extend over many years and create recurring fixed obligations.
Vaikutus: Affects balance sheet lease liabilities and future cash commitments
The company is subject to claims and litigation in the normal course of business, including IP-related disputes.
Vaikutus: May require reserves or disclosure of contingent liabilities
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
United Therapeutics Corporation
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
Vystar Corp
VYST · Fabricated Rubber Products, NEC
Vystar Corp is a U.S.-based company built around two product families: Vytex natural rubber latex materials and RxAir UV-C air purification devices.
Intellia Therapeutics, Inc.
NTLA · In Vitro & In Vivo Diagnostic Substances
Intellia Therapeutics is a clinical-stage biopharmaceutical company built around CRISPR-based gene editing and related delivery technologies.
Inhibikase Therapeutics, Inc.
IKT · Biological Products, (No Diagnostic Substances)
Arrowhead Pharmaceuticals, Inc
ARWR · Pharmaceutical Preparations
Arrowhead Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing RNA interference medicines that silence disease-causing genes.
Ardelyx, Inc
ARDX · Pharmaceutical Preparations
Päivitetty: 24.9.2026